JUBLPHARMA

Jubilant Pharmova Share Price

₹1,194.00 +28.3 (2.43%)

14 Jul, 2025 18:04

SIP TrendupStart SIP in JUBLPHARMA

Start SIP

Performance

  • Low
  • ₹1,159
  • High
  • ₹1,202
  • 52 Week Low
  • ₹702
  • 52 Week High
  • ₹1,310
  • Open Price₹1,166
  • Previous Close₹1,166
  • Volume319,145

Investment Returns

  • Over 1 Month + 9.12%
  • Over 3 Month + 30.02%
  • Over 6 Month + 29.16%
  • Over 1 Year + 65.44%
SIP Lightning

Smart Investing Starts Here Start SIP with Jubilant Pharmova for Steady Growth!

Invest Now

Jubilant Pharmova Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 22.7
  • PEG Ratio
  • 0
  • Market Cap Cr
  • 19,018
  • P/B Ratio
  • 3.2
  • Average True Range
  • 38.23
  • EPS
  • 35.03
  • Dividend Yield
  • 0.4
  • MACD Signal
  • 27.23
  • RSI
  • 60.32
  • MFI
  • 67.51

Jubilant Pharmova Financials

Jubilant Pharmova Technicals

EMA & SMA

Current Price
₹1,194.00
+ 28.3 (2.43%)
pointer
  • stock-down_img
  • Bearish Moving Average 0
  • stock-up_img
  • Bullish Moving Average 16
  • 20 Day
  • ₹1,164.32
  • 50 Day
  • ₹1,107.76
  • 100 Day
  • ₹1,056.85
  • 200 Day
  • ₹1,001.02

Resistance and Support

1184.87 Pivot Speed
  • R3 1,253.03
  • R2 1,227.27
  • R1 1,210.63
  • S1 1,168.23
  • S2 1,142.47
  • S3 1,125.83

What's your outlook on Jubilant Pharmova?

You can only vote once!

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Jubilant Pharmova Ltd. is a global pharmaceutical company engaged in radiopharma, allergy immunotherapy, CDMO sterile injectables, CRDMO, and generics. It operates manufacturing facilities across regulated markets, offering innovative solutions in oncology, autoimmune disorders, and various therapeutic areas.

Jubilant Pharmova has an operating revenue of Rs. 7,234.50 Cr. on a trailing 12-month basis. An annual revenue growth of 8% is good, Pre-tax margin of 14% is healthy, ROE of 13% is good. The company has a reasonable debt to equity of 34%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 7% and 10% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around -2% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 60 which is a FAIR score but needs to improve its earnings, a RS Rating of 85 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 67 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of A is the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Jubilant Pharmova Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-05-16 Audited Results & Final Dividend
2025-01-31 Quarterly Results
2024-10-25 Quarterly Results
2024-07-19 Quarterly Results
2024-05-29 Audited Results & Final Dividend
Date Purpose Remarks
2025-07-25 FINAL Rs.5.00 per share(500%)Final Dividend
2024-08-02 FINAL Rs.5.00 per share(500%)Final Dividend
2023-08-10 FINAL Rs.5.00 per share(500%)Final Dividend
2022-08-12 FINAL Rs.5.00 per share(500%)Final Dividend
2021-08-06 FINAL Rs.5.00 per share(500%)Final Dividend
View More

Jubilant Pharmova F&O

Jubilant Pharmova Shareholding Pattern

50.68%
3.66%
1.36%
17.23%
0%
17.74%
9.33%

About Jubilant Pharmova

  • NSE Symbol
  • JUBLPHARMA
  • BSE Symbol
  • 530019
  • Managing Director
  • Mr. Priyavrat Bhartia
  • ISIN
  • INE700A01033

Similar Stocks to Jubilant Pharmova

Jubilant Pharmova FAQs

Jubilant Pharmova share price is ₹1,194 As on 14 July, 2025 | 17:50

The Market Cap of Jubilant Pharmova is ₹19018.2 Cr As on 14 July, 2025 | 17:50

The P/E ratio of Jubilant Pharmova is 22.7 As on 14 July, 2025 | 17:50

The PB ratio of Jubilant Pharmova is 3.2 As on 14 July, 2025 | 17:50

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23